

Jayanthi S Lea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6538407/publications.pdf>

Version: 2024-02-01

85
papers

2,598
citations

218677

26
h-index

206112

48
g-index

86
all docs

86
docs citations

86
times ranked

4066
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Papillomavirusâ€Positive and â€Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1280-1290.e7.	0.7	9
2	Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?. <i>Practical Radiation Oncology</i> , 2022, 12, e123-e134.	2.1	1
3	Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2022, 46, 713-724.	3.7	2
4	Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. , 2022, 10, e003960.		22
5	Bloodâ€based biomarkers of human papillomavirusâ€associated cancers: A systematic review and metaâ€analysis. <i>Cancer</i> , 2021, 127, 850-864.	4.1	24
6	Stage IVA cervical cancer: outcomes of disease related complications and treatment. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 518-523.	2.5	5
7	Tumor Necrotic Debris and High Nuclear Grade. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 162-168.	1.3	7
8	Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. <i>Journal of Pathology</i> , 2021, 254, 20-30.	4.5	9
9	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
10	A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1423-1431.	0.8	14
11	NCCN Guidelinesâ€ Insights: Uterine Neoplasms, Version 3.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 888-895.	4.9	113
12	Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers. <i>Cell</i> , 2021, 184, 4531-4546.e26.	28.9	42
13	Identification of PARP-7 substrates reveals a role for MARYlation in microtubule control in ovarian cancer cells. <i>ELife</i> , 2021, 10, .	6.0	39
14	PD-L1 Expression in Endocervical Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 742-752.	3.7	10
15	ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 282-291.	4.1	20
16	A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 464-471.	0.8	66
17	Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. <i>Gynecologic Oncology</i> , 2020, 156, 100-106.	1.4	14
18	Specimen Fragmentation and Loop Electrosurgical Excision Procedure and Cold Knife Cone Biopsy Outcomes. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 27-33.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Cervical Adenocarcinoma. American Journal of Surgical Pathology, 2020, 44, 247-254.	3.7	21
20	Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey. Gynecologic Oncology Reports, 2020, 34, 100620.	0.6	3
21	The impact of intimate partner violence on breast and cervical cancer survivors in an integrated, safety-net setting. Journal of Cancer Survivorship, 2020, 14, 906-914.	2.9	8
22	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. American Journal of Surgical Pathology, 2020, 44, 1050-1060.	3.7	34
23	Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists. Gynecologic Oncology Reports, 2020, 33, 100617.	0.6	4
24	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Science Translational Medicine, 2020, 12, .	12.4	59
25	Multimodality Imaging of Uterine Cervical Malignancies. American Journal of Roentgenology, 2020, 215, 292-304.	2.2	11
26	Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma. PLoS ONE, 2020, 15, e0229569.	2.5	16
27	Value of Intratumoral Metabolic Heterogeneity and Quantitative ¹⁸ F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer. American Journal of Roentgenology, 2020, 214, 908-916.	2.2	21
28	Title is missing!. , 2020, 15, e0229569.		0
29	Title is missing!. , 2020, 15, e0229569.		0
30	Title is missing!. , 2020, 15, e0229569.		0
31	Title is missing!. , 2020, 15, e0229569.		0
32	Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study. Journal of Oncology, 2019, 2019, 1-9.	1.3	10
33	Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. Journal of Controlled Release, 2019, 300, 154-160.	9.9	61
34	Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?. International Journal of Gynecological Pathology, 2019, 38, 533-542.	1.4	25
35	Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1137-1141.	1.3	3
36	Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1220-1224.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Preoperative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 1020-1028.	1.7	30
38	Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 797-801.	1.3	3
39	Locally Advanced Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 447-451.	1.3	6
40	Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 792-796.	1.3	8
41	Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 933-937.	1.3	9
42	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	1.6	61
43	The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1225-1230.	1.3	15
44	Dysregulation of fibulin-5 and matrix metalloproteases in epithelial ovarian cancer. <i>Oncotarget</i> , 2018, 9, 14251-14267.	1.8	19
45	The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. <i>Gynecologic Oncology</i> , 2017, 144, 586-591.	1.4	10
46	A STING-activating nanovaccine for cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 648-654.	31.5	649
47	Sparse feature selection for classification and prediction of metastasis in endometrial cancer. <i>BMC Genomics</i> , 2017, 18, 233.	2.8	19
48	Response to "Towards implementation of sexual healthcare". <i>Gynecologic Oncology Reports</i> , 2017, 20, 139.	0.6	0
49	Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study. <i>Oncotarget</i> , 2017, 8, 14395-14407.	1.8	76
50	A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. <i>Oncotarget</i> , 2017, 8, 50489-50499.	1.8	23
51	Factors influencing primary treatment of midline vulvar cancers. <i>Gynecologic Oncology</i> , 2016, 142, 133-138.	1.4	0
52	Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. <i>Brachytherapy</i> , 2016, 15, 341-346.	0.5	1
53	Sparse Feature Selection for Classification and Prediction of Metastasis in Endometrial Cancer. , 2016, , ,		0
54	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. <i>Molecular Systems Biology</i> , 2015, 11, 842.	7.2	10

#	ARTICLE	IF	CITATIONS
55	Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management. <i>Future Oncology</i> , 2015, 11, 309-322.	2.4	16
56	Ovarian involvement in endometrioid adenocarcinoma of uterus. <i>Gynecologic Oncology</i> , 2015, 138, 532-535.	1.4	32
57	A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 484-492.	2.5	56
58	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015, 125, 4063-4076.	8.2	79
59	Malignant ovarian germ cell tumor " Role of surgical staging and gonadal dysgenesis. <i>Gynecologic Oncology</i> , 2014, 134, 84-89.	1.4	33
60	Adnexal masses requiring surgical intervention in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , 2014, 134, 552-555.	1.4	4
61	Factors associated with clinical trial screening failures in gynecologic oncology. <i>Gynecologic Oncology</i> , 2014, 134, 450-454.	1.4	7
62	Correlation of Severe (Grade 3-4) Late Recto-Sigmoid and Bladder Toxicity in Archival Patients with GEC-ESTRO OAR Dose-Volume Parameters. <i>Brachytherapy</i> , 2013, 12, S50.	0.5	0
63	Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. <i>Gynecologic Oncology</i> , 2012, 127, 43-46.	1.4	14
64	Cervical Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2012, 39, 233-253.	1.9	57
65	Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T. <i>NMR in Biomedicine</i> , 2012, 25, 1321-1330.	2.8	58
66	Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. <i>Gynecologic Oncology</i> , 2012, 124, 508-511.	1.4	4
67	In vitro chemosensitivity assay for patients with gynecologic sarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13078-e13078.	1.6	0
68	Recurrence patterns in patients with stage IIIC1 versus IIIC2 endometrial adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15501-e15501.	1.6	0
69	Recurrent Phyllodes Tumor of the Vulva: A Case Report With Review of Diagnostic Criteria and Differential Diagnosis. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 294-297.	1.4	16
70	Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 108, 123-127.	2.3	25
71	Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 180.e1-180.e7.	1.3	16
72	Implications of EGFR inhibition in ovarian cancer cell proliferation. <i>Gynecologic Oncology</i> , 2008, 109, 411-417.	1.4	38

#	ARTICLE	IF	CITATIONS
73	Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells. <i>Reproductive Sciences</i> , 2007, 14, 20-28.	2.5	37
74	Understanding the Mechanisms of FHIT Inactivation in Cervical Cancer for Biomarker Development. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 329-337.	1.7	10
75	Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 674-679.	1.3	47
76	P16 as a molecular biomarker of cervical adenocarcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 668-673.	1.3	49
77	Adenocarcinoma of the cervix. <i>Current Treatment Options in Oncology</i> , 2004, 5, 119-127.	3.0	38
78	Cervical adenocarcinoma survival among Hispanic and white women: A multicenter cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 640-644.	1.3	9
79	Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. <i>Gynecologic Oncology</i> , 2003, 91, 558-562.	1.4	54
80	Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial. <i>Journal of reproductive medicine, The</i> , 2003, 48, 751-5.	0.2	9
81	Management of low-risk gestational trophoblastic neoplasia in indigent women. <i>Journal of reproductive medicine, The</i> , 2003, 48, 780-4.	0.2	5
82	Stage IIBâ€“IVB Cervical Adenocarcinoma: Prognostic Factors and Survival. <i>Gynecologic Oncology</i> , 2002, 84, 115-119.	1.4	58
83	Early-Stage Cervical Adenocarcinoma Treated by Surgical Intent: The Role of Para-aortic Lymph Node Dissection. <i>Gynecologic Oncology</i> , 2002, 84, 285-288.	1.4	13
84	Endocervical Curettage at Conization to Predict Residual Cervical Adenocarcinoma in Situ. <i>Gynecologic Oncology</i> , 2002, 87, 129-132.	1.4	56
85	Complete Groin Lymphadenectomy with Preservation of the Fascia Lata in the Treatment of Vulvar Carcinoma. <i>Gynecologic Oncology</i> , 2000, 77, 314-318.	1.4	64